WO2010150245A1 - Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts - Google Patents

Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts Download PDF

Info

Publication number
WO2010150245A1
WO2010150245A1 PCT/IL2010/000486 IL2010000486W WO2010150245A1 WO 2010150245 A1 WO2010150245 A1 WO 2010150245A1 IL 2010000486 W IL2010000486 W IL 2010000486W WO 2010150245 A1 WO2010150245 A1 WO 2010150245A1
Authority
WO
WIPO (PCT)
Prior art keywords
cannabis
composition
ointment
condition
extract
Prior art date
Application number
PCT/IL2010/000486
Other languages
French (fr)
Inventor
Ephraim Philip Lansky
Original Assignee
Tikun Olam Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tikun Olam Ltd. filed Critical Tikun Olam Ltd.
Publication of WO2010150245A1 publication Critical patent/WO2010150245A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)

Definitions

  • This invention relates to preparations with anti-inflammatory properties, hi particular, those preparations containing as active ingredients extracts of flowers and seeds of Cannabis sp.
  • cannabinoids The anti-inflammatory properties of cannabinoids are well-known (Mechoulam, R. "Alkaloids in Cannabis sativa L.”; In: The Alkaloids; Brossi, A, Ed.; San Diego: Academic Press, 1988, 77-93). Indeed, cannabis has been a component of traditional folk remedies, in particular for skin conditions, in many cultures (see, for example * Oumeish, O. Y., "Traditional Arabic Medicine in Dermatology,” Clinics in Dermatology 1999, 17, 13-20, and Mamedov, N.; Gardner, Z.; Craker, L. E., "Medicinal Plants Used in Russia and Central Asia for the Treament of Skin Conditions," J. Herbs, Spices, Med. Plants 2005, 11, 191- 222).
  • Patent Application 11/327,693 discloses the use of cannabinol derivatives for treatment inter alia of diseases which are the result of inflammation such as Crohn's disease, ulcerative colitis, and some forms of asthma.
  • U.S. Patent Application 11/115,983 discloses a combination of THC and CBD for use to alleviate pain associated with cancer. More relevant to the present invention, a number of inventions have been disclosed that include cannabinoids as therapeutic agents for treatment of skin conditions, or that disclose dermal or transdermal delivery methods for cannabinoids.
  • PCT Application WO2007/001891 discloses a composition in which a cannabinoid is combined with a permeation enhancer for improved transdermal delivery of the cannabinoid
  • PCT Application WO2008/024408 discloses a composition for transdermal delivery of a cannabinoid that reduces the likelihood of the patient's using the cannabinoid as a drug of abuse.
  • a cannabinoid is used in combination with another therapeutic agent.
  • U.S. Patent Application 11/510,390 discloses a combination therapy in which a cannabinoid receptor agonist (e.g. THC) is combined with a cannabinoid receptor antagonist that serves to potentiate the activity of the cannabinoid receptor agonist.
  • compositions including inter alia compositions containing a cannabinoid and a long-chain unsaturated fatty acid, for treatment of immunoproliferative skin disorders such as psoriasis.
  • compositions have in common that they comprise a limited set of specific compounds.
  • the cannabinoids in these compounds are either extracted and purified from Cannabis sp., or are synthetic derivatives or analogs of naturally-occurring cannabinoids. It is known, however, that the pharmaceutical activity of cannabis extract is different than that of pure cannabinoids such as THC, and the possibility of synergistic effects among the components of cannabis extract has been hypothesized (Ben-Shabat, S; Fride, E.; Sheskin, T.; Tamiri, T.; Rhee, M. H.; Vogel, Z.; Bisogno, T.; De Petrocellis, L.; Di Marzio, V.; Mechoulam, R.
  • the invention disclosed herein comprises a mixture of extracts from flowers and seeds of Cannabis sp.
  • the anti-inflammatory properties of these extracts is used to produce an all- natural composition that is effective against conditions, particularly skin conditions, that are characterized by inflammation of tissues.
  • the particular combination of these two extracts has a synergistic effect over either extract used alone.
  • the composition can also be incorporated into an ointment for dermal or transdermal application of the composition. It is therefore an object of the invention to disclose a composition for treating a condition, said composition adapted for application to the skin and said condition characterized by inflammation of tissue, wherein said composition comprises a mixture of cannabis flower extract and cannabis seed extract.
  • composition wherein said cannabis flower extract is obtained by extraction of dried flowers of Cannabis sp. by ethanol. It is a further object of this invention to disclose such a composition, wherein said cannabis flower extract is obtained from a hybrid plant of Cannabis indica and Cannabis sativa. It is a further object of this invention to disclose such a composition as defined in any of the above, wherein said hybrid plant is about 80% Cannabis indica and about 20% Cannabis sativa.
  • Cannabis sativa is a genotype the seeds of which have a high gamma linolenic acid content.
  • composition comprises said cannabis flower extract and said base in a ratio of about 5:95.
  • transdermal ointment for treating a condition characterized by inflammation of tissue, wherein said transdermal ointment comprises a composition according to claim 1 compounded with a vehicle.
  • step of obtaining cannabis flower extract further includes the additional step of extracting cannabis flowers with ethanol.
  • step of obtaining cannabis flower extract further includes the additional step of obtaining dried flowers of Cannabis sp. It is a further object of this invention to provide such a method, wherein said step of obtaining cannabis flower extract further includes the additional step of extracting cannabis flowers obtained from a hybrid plant of Cannabis indica and Cannabis sativa.
  • step of obtaining cannabis seed extract further comprises the step of extracting cannabis seeds using supercritical CO 2 .
  • step of obtaining cannabis seed extract further comprises the step of extracting cannabis seeds by cold pressing.
  • step of obtaining cannabis seed extract further comprises the additional steps of (a) obtaining seeds of Cannabis sativa; and (b) producing an extract from said seeds.
  • step of obtaining seeds of Cannabis sativa further comprises the additional step of obtaining seeds from a genotype of Cannabis sativa the seeds of which have a high gamma linolenic acid content.
  • step of obtaining cannabis seed extract further comprises the additional step of preparing a base comprising about 85% cannabis seed extract, about 10% pomegranate seed oil, and about
  • step of mixing said cannabis flower extract and said cannabis seed extract further includes the additional step of mixing said cannabis flower extract and said base in a ratio of about 5:95.
  • cannabis flowers and “cannabis seed” as used herein refer to the flowers and seeds of any species of plant in the genus Cannabis.
  • the terms “extraction,” and “extracting” refer to any process known in the art by which soluble components of plant material are separated from the plant by dissolving them in a solvent, and the term “extract” refers to any solution thus obtained.
  • the terms as used herein do not imply any restriction or limitation on the details of the process or the specific content of the extract thus produced.
  • the term “DMSO” refers to the chemical dimethylsulfoxide.
  • the basic composition disclosed in the present invention comprises two components, an extract of cannabis flowers (Cannabis Flos) and an extract of cannabis seed (Cannabis Semen). The details of the extraction processes are well-known to those skilled in the art.
  • the general methods by which the extracts are obtained in the preferred embodiments are as follows.
  • the cannabis flower extract is obtained by ethanol extraction of cannabis flowers.
  • the cannabis flower extract is obtained by extraction by 95% ethanol derived from fermentation and repeated distillation of pomegranate juice (i.e. the juice of the fruit of Punica grantwn).
  • the cannabis flower extract is obtained by extraction by 95% ethanol derived from fermentation and repeated distillation of pomegranate juice obtained from organically grown of dried flowers of Cannabis sp.
  • the cannabis seed extract is obtained by cold- pressing.
  • the cannabis seed extract is obtained by supercritical fluid extraction using CO 2 as the solvent.
  • the cannabis flower extract is obtained from a hybrid plant of about 80% Cannabis indica and about 20% Cannabis sativa.
  • the hybrid plants from the which extracts are prepared are organically grown.
  • the cannabis seed extract is obtained from seeds of Cannabis sativa.
  • the cannabis plants from which the seed extract is obtained are organically grown Cannabis sativa.
  • the organically grown Cannabis sativa from which the seed extract is prepared is a genotype with a high concentration of gamma linolenic acid (GLA) in its oil.
  • GLA gamma linolenic acid
  • This genotype is preferred because these seeds provide a stronger synergistic effect when their extract is combined with cannabis flower extract.
  • the exact origin of this synergistic effect remains obscure; it appears to originate from the unexpected benefit of the combined action of THC found in cannabis flower extract with at least one of the literally dozens of natural products (e.g. other cannabinoids, terpenoids, fatty acids, sterols, etc.) found in cannabis seed extract.
  • the ratio of cannabis flower extract to cannabis seed extract within the composition is composition between about 1:99 and about 99:1. In a more preferred embodiment of the invention, the ratio of cannabis flower extract to cannabis seed extract within the composition is composition between about 5:95 and about 20:80. In a most preferred embodiment of the invention, the cannabis seed extract is provided as a base comprising about 10% pomegranate seed oil, about 5% wheat kernel oil, and about 85% cannabis seed extract, -and the ratio of cannabis flower extract to the base containing cannabis seed extract is about 5:95.
  • the composition is compounded with an appropriate vehicle in order to produce a transdermal ointment for direct application to the skin.
  • the vehicle is Cera Alba (white beeswax).
  • the ointment comprises between about 5% and about 15% of the composition described above. In a preferred embodiment of the invention, the ointment comprises between about 8% and about 12% of the composition described above. In a most preferred embodiment of the invention, the ointment comprises about 9% of the composition described above.
  • the ointment further comprises DMSO.
  • the DMSO is added in order to facilitate transdermal penetration of the composition into subdermal tissues.
  • the ointment comprises between about 1% and about 25% DMSO.
  • the ointment comprises between about 5% and about 15% DMSO.
  • the ointment comprises about 10% DMSO.
  • the composition is provided in a form adapted for other parenteral uses including, as non-limiting examples, intravenous, nasopharyngeal, and inhalation.
  • composition and ointment described above are designed to treat, lessen the effects of, and/or palliate the symptoms of a number of conditions characterized by inflammation of tissues. As described in detail in the examples presented below, these conditions include, but are by no means limited to, psoriasis, psoriatic arthritis, atopic dermatitis, and rheumatoid arthritis.
  • the present invention also provides a method for preparing a composition for the treatment of a condition characterized by inflammation of tissues.
  • the method comprises the steps of (a) obtaining cannabis flower extract; (b) obtaining cannabis seed extract; and (c) mixing said cannabis flower extract and said cannabis seed extract in a predetermined ratio until a homogeneous composition is obtained.
  • This general method will produce any of the embodiments of the composition described above, according to the ratio of the two extracts, the specific cannabis plants, and specific extraction method used.
  • the present invention also provides a method for preparing a transdermal ointment for the treatment of a condition characterized by inflammation of tissues.
  • the method comprises the steps of (a) obtaining a composition for treatment of a condition characterized by inflammation of tissues as defined above and (b) compounding a said composition with a vehicle in a predetermined ratio until a homogeneous ointment is obtained.
  • An additional embodiment of the method includes the step of adding a predetermined quantity of DMSO to the vehicle in order to prepare a transdermal ointment with increased ability to penetrate to subdermal tissues.
  • Cannabis flower extract as used in the invention herein disclosed.
  • Flowers of the Erez hybrid of Cannabis indica / Cannabis sativa were carefully picked at maturity and manually trimmed with steel scissors to remove leaves.
  • the flowers were then immediately placed in an opaque plain brown paper bag and wrapped up by the bag's own paper body.
  • the wrapped bag was then left in a room at ambient temperature for at least two weeks and most preferably for three weeks at which time the flowers have surrendered over 80% of their fresh weight as humidity and are quite dry to the touch.
  • the whole completely dry trimmed flowers are then weighed and 40 grams of material are placed in a dry, clean 500 ml glass bottle. This requires some little nudging but does not require outright pressing or crushing.
  • Nonsteroidal anti-inflammatory drugs provided orally and topically in an ointment had afforded moderate relief for a couple of hours after each use, with gradual return of the pain.
  • the patient then began a course of treatment with the ointment disclosed herein in place of the NSAIDs.
  • the patient applied a small amount (-0.3 ml) of the ointment topically to the hip and massaged it in.
  • the treatment was repeated on several occasions over the course of a week.

Abstract

The present invention discloses a composition for treating a condition which is adapted for application to the skin. The condition is characterized by inflammation of tissue. The composition comprises a mixture of cannabis flower extract and cannabis seed extract.

Description

PHARMACEUTICAL ANDCOSMECEUTICAL COMPOSITIONS CONTAINING CANNABIS FLOWER AND SEED EXTRACTS
FIELD OF THE INVENTION
This invention relates to preparations with anti-inflammatory properties, hi particular, those preparations containing as active ingredients extracts of flowers and seeds of Cannabis sp.
BACKGROUND OF THE INVENTION
The anti-inflammatory properties of cannabinoids are well-known (Mechoulam, R. "Alkaloids in Cannabis sativa L."; In: The Alkaloids; Brossi, A, Ed.; San Diego: Academic Press, 1988, 77-93). Indeed, cannabis has been a component of traditional folk remedies, in particular for skin conditions, in many cultures (see, for example* Oumeish, O. Y., "Traditional Arabic Medicine in Dermatology," Clinics in Dermatology 1999, 17, 13-20, and Mamedov, N.; Gardner, Z.; Craker, L. E., "Medicinal Plants Used in Russia and Central Asia for the Treament of Skin Conditions," J. Herbs, Spices, Med. Plants 2005, 11, 191- 222). Thus, there is a growing interest in the use of cannabinoids in the treatment of disease (see, for example, Ben Amar, M., "Cannabinoids in Medicine: a Review of Their Therapeutic Potential," J. Ethnopharacol 2006, 105, 1-25, and Politi, M.; Peschel, W.; Wilson, R; Zloh, M.; Prieto, J. M.; Heinrich, M. "Direct NMR Analysis of Cannabis Water Extracts and Tinctures and Semi-Quantitative Data on Δ9-THC and Δ9-THC-acid," Phytochemistry 2008, 69, 562, and references therein).
While cannabinoids have been investigated as possible therapeutic agents for a wide variety of conditions, ranging from glaucoma to Tourette's syndrome, and Sativex , which contains THC and cannabidiol (CBD), has been licensed in Canada as a therapy against multiple sclerosis, most cannabinoid-containing preparations thus far developed have been for the treatment of conditions characterized by inflammation. Thus, PCT Application WO2009/004302 discloses the use of a tetrahydrocannabinol (THC) in a medicament for treatment of inflammatory bowel disease. U.S. Patent Application 11/327,693 discloses the use of cannabinol derivatives for treatment inter alia of diseases which are the result of inflammation such as Crohn's disease, ulcerative colitis, and some forms of asthma. U.S. Patent Application 11/115,983 discloses a combination of THC and CBD for use to alleviate pain associated with cancer. More relevant to the present invention, a number of inventions have been disclosed that include cannabinoids as therapeutic agents for treatment of skin conditions, or that disclose dermal or transdermal delivery methods for cannabinoids. For example, PCT Application WO2007/001891 discloses a composition in which a cannabinoid is combined with a permeation enhancer for improved transdermal delivery of the cannabinoid, while PCT Application WO2008/024408 discloses a composition for transdermal delivery of a cannabinoid that reduces the likelihood of the patient's using the cannabinoid as a drug of abuse.
In addition to those inventions in which a cannabinoid is combined with a material that is not specifically directed against a medical condition, a number of inventions have been diclosed in which a cannabinoid is used in combination with another therapeutic agent. For example, U.S. Patent Application 11/510,390 discloses a combination therapy in which a cannabinoid receptor agonist (e.g. THC) is combined with a cannabinoid receptor antagonist that serves to potentiate the activity of the cannabinoid receptor agonist. PCT Application WO2005/102296 discloses a number of compositions, including inter alia compositions containing a cannabinoid and a long-chain unsaturated fatty acid, for treatment of immunoproliferative skin disorders such as psoriasis.
All of these compositions have in common that they comprise a limited set of specific compounds. The cannabinoids in these compounds are either extracted and purified from Cannabis sp., or are synthetic derivatives or analogs of naturally-occurring cannabinoids. It is known, however, that the pharmaceutical activity of cannabis extract is different than that of pure cannabinoids such as THC, and the possibility of synergistic effects among the components of cannabis extract has been hypothesized (Ben-Shabat, S; Fride, E.; Sheskin, T.; Tamiri, T.; Rhee, M. H.; Vogel, Z.; Bisogno, T.; De Petrocellis, L.; Di Marzio, V.; Mechoulam, R. "An Entourage Effect: Inactive Endogenous Fatty Acid Glycerol Esters Enhance 2-arachidonoyl-glycerol Cannabinoid Activity," Eur. J. Pharmacol. 1998, 353, 23- 31; Russo, E.; Guy, G. W. "A Tale of Two Cannabinoids: the Therapeutic Rationale for Combining Tetrahdyrocannabinol and Cannabidiol," Med Hypoth. 2006, 66, 234). Nonetheless, therapeutic compositions that are based on cannabis extract rather than on specific cannabinoids remain unknown in the art. Thus, there remains a long-felt need for such compositions that rely on these synergistic effects, especially in the treatment of diseases characterized by inflammation of tissues. SUMMARY OF THE INVENTION
The invention disclosed herein comprises a mixture of extracts from flowers and seeds of Cannabis sp. The anti-inflammatory properties of these extracts is used to produce an all- natural composition that is effective against conditions, particularly skin conditions, that are characterized by inflammation of tissues. The particular combination of these two extracts has a synergistic effect over either extract used alone. The composition can also be incorporated into an ointment for dermal or transdermal application of the composition. It is therefore an object of the invention to disclose a composition for treating a condition, said composition adapted for application to the skin and said condition characterized by inflammation of tissue, wherein said composition comprises a mixture of cannabis flower extract and cannabis seed extract.
It is a further object of this invention to disclose such a composition, wherein the ratio of cannabis flower extract to cannabis seed extract is between about 1:99 and about 99:1. It is a further object of this invention to disclose such a composition, wherein the ratio of cannabis flower extract to cannabis seed extract is between about 20:80 and about 5:95. It is a further object of this invention to disclose such a composition, wherein the ratio of cannabis flower extract to cannabis seed extract is about 5:95.
It is a further object of this invention to disclose such a composition, wherein said cannabis flower extract is obtained by extraction with ethanol.
It is a further object of this invention to disclose such a composition, wherein said cannabis flower extract is obtained by extraction of dried flowers of Cannabis sp. by ethanol. It is a further object of this invention to disclose such a composition, wherein said cannabis flower extract is obtained from a hybrid plant of Cannabis indica and Cannabis sativa. It is a further object of this invention to disclose such a composition as defined in any of the above, wherein said hybrid plant is about 80% Cannabis indica and about 20% Cannabis sativa.
It is a further object of this invention to disclose such a composition as defined in any of the above, wherein said ethanol is obtained from fermentation and distillation of fruits of Punica grantum.
It is a further object of this invention to disclose such a composition, wherein said Punica grantum is organically grown.
It is a further object of this invention to disclose such a composition as defined in any of the above, wherein said cannabis seed extract is obtained by supercritical fluid extraction by CO2. It is a further object of this invention to disclose such a composition as defined in any of the above, wherein said cannabis seed extract is obtained by cold pressing.
It is a further object of this invention to disclose such a composition as defined in any of the above, wherein said cannabis seed extract is obtained from seeds of Cannabis sativa.
It is a further object of this invention to disclose such a composition as defined in any of the above, wherein said Cannabis sativa is a genotype the seeds of which have a high gamma linolenic acid content.
It is a further object of this invention to disclose such a composition as defined in any of the above, wherein said Cannabis sativa is organically grown.
It is a further object of this invention to disclose such a composition as defined in any of the above, wherein said cannabis seed extract is provided in a base comprising about 85% cannabis seed extract, about 10% pomegranate seed oil, and about 5% wheat kernel oil.
It is a further object of this invention to disclose such a composition, wherein said composition comprises said cannabis flower extract and said base in a ratio of about 5:95.
It is a further object of this invention to disclose such a composition as defined in any of the above, wherein said condition is atopic dermatitis.
It is a further object of this invention to disclose such a composition as defined in any of the above, wherein said condition is psoriasis.
It is a further object of this invention to disclose such a composition as defined in any of the above, wherein said condition is psoriatic arthritis.
It is a further object of this invention to disclose such a composition as defined in any of the above, wherein said condition is rheumatoid arthritis.
It is a further object of this invention to disclose a transdermal ointment for treating a condition characterized by inflammation of tissue, wherein said transdermal ointment comprises a composition according to claim 1 compounded with a vehicle.
It is a further object of this invention to disclose such an ointment, wherein said ointment comprises between about 5% and about 15% of said composition.
It is a further object of this invention to disclose such an ointment, wherein said ointment comprises between about 8% and about 12% of said composition.
It is a further object of this invention to disclose such an ointment, wherein said ointment comprises about 9% of said composition.
It is a further object of this invention to disclose such an ointment as defined in any of the above, wherein said vehicle is Cera Alba. It is a further object of this invention to disclose such an ointment as defined in any of the above, further comprising DMSO.
It is a further object of this invention to disclose such an ointment, wherein said ointment comprises between about 1% and about 25% DMSO.
It is a further object of this invention to disclose such an ointment, wherein said ointment comprises between about 5% and about 15% DMSO.
It is a further object of this invention to disclose such an ointment, wherein said ointment comprises about 10% DMSO.
It is a further object of this invention to disclose such an ointment, wherein said condition is atopic dermatitis.
It is a further object of this invention to disclose such an ointment, wherein said condition is psoriasis.
It is a further object of this invention to disclose such an ointment, wherein said condition is psoriatic arthritis.
It is a further object of this invention to disclose such an ointment, wherein said condition is rheumatoid arthritis.
It is a further object of this invention to provide a method for producing a composition adapted for treatment of a condition characterized by inflammation of tissues, said method comprising the steps of (a) obtaining cannabis flower extract; (b) obtaining cannabis seed extract; and (c) mixing said cannabis flower extract and said cannabis seed extract in a predetermined ratio until a homogeneous composition is obtained.
It is a further object of this invention to provide such a method, wherein said predetermined ratio is between about 1:99 and about 99:1.
It is a further object of this invention to provide such a method, wherein said predetermined ratio is between about 20:80 and about 5:95.
It is a further object of this invention to provide such a method, wherein said predetermined ratio is about 5:95.
It is a further object of this invention to provide such a method, wherein said step of obtaining cannabis flower extract further includes the additional step of extracting cannabis flowers with ethanol.
It is a further object of this invention to provide such a method, wherein said step of obtaining cannabis flower extract further includes the additional step of obtaining dried flowers of Cannabis sp. It is a further object of this invention to provide such a method, wherein said step of obtaining cannabis flower extract further includes the additional step of extracting cannabis flowers obtained from a hybrid plant of Cannabis indica and Cannabis sativa.
It is a further object of this invention to provide such a method, wherein said hybrid plant is about 80% Cannabis indica and about 20% Cannabis sativa.
It is a further object of this invention to provide such a method, further comprising the additional steps of (a) fermenting and distilling alcohol from fruits of Punica grantum; and
(b) using said alcohol in said step of extracting cannabis flowers.
It is a further object of this invention to provide such a method, wherein said Punica grantum is organically grown.
It is a further object of this invention to provide such a method, wherein said step of obtaining cannabis seed extract further comprises the step of extracting cannabis seeds using supercritical CO2.
It is a further object of this invention to provide such a method, wherein said step of obtaining cannabis seed extract further comprises the step of extracting cannabis seeds by cold pressing.
It is a further object of this invention to provide such a method, wherein said step of obtaining cannabis seed extract further comprises the additional steps of (a) obtaining seeds of Cannabis sativa; and (b) producing an extract from said seeds.
It is a further object of this invention to provide such a method, wherein said step of obtaining seeds of Cannabis sativa further comprises the additional step of obtaining seeds from a genotype of Cannabis sativa the seeds of which have a high gamma linolenic acid content.
It is a further object of this invention to provide such a method, wherein said Cannabis sativa is organically grown.
It is a further object of this invention to provide such a method, wherein said step of obtaining cannabis seed extract further comprises the additional step of preparing a base comprising about 85% cannabis seed extract, about 10% pomegranate seed oil, and about
5% wheat kernel oil.
It is a further object of this invention to provide such a method, wherein said step of mixing said cannabis flower extract and said cannabis seed extract further includes the additional step of mixing said cannabis flower extract and said base in a ratio of about 5:95.
It is a further object of this invention to provide such a method as defined in any of the above, wherein said condition is atopic dermatitis. It is a farther object of this invention to provide such a method as defined in any of the above, wherein said condition is psoriasis.
It is a further object of this invention to provide such a method as defined in any of the above, wherein said condition is psoriatic arthritis.
It is a farther object of this invention to provide such a method as defined in any of the above, wherein said condition is rheumatoid arthritis.
It is a further object of this invention to provide a method for producing a transdermal ointment adapted for the treatment of a condition characterized by inflammation of tissues, said method comprising the steps of: (a) preparing a composition adapted for the treatment of a condition characterized by inflammation of tissues according to the method as defined in any of the above; and (b) compounding said mixture with a vehicle in a predetermined ratio.
It is a further object of this invention to provide such a method for producing a transdermal ointment, wherein said vehicle is Cera Alba.
It is a further object of this invention to provide such a method for producing a transdermal ointment as defined in any of the above, wherein said predetermined ratio is between about
5:95 and about 15:85.
It is a further object of this invention to provide such a method for producing a transdermal ointment as defined in any of the above, wherein said predetermined ratio is between about
8:92 and about 12:88.
It is a further object of this invention to provide such a method for producing a transdermal ointment as defined in any of the above, wherein said predetermined ratio is about 9:91.
It is a farther object of this invention to provide such a method for producing a transdermal ointment as defined in any of the above, further comprising the additional step of adding a predetermined amount of DMSO to said vehicle.
It is a farther object of this invention to provide such a method for producing a transdermal ointment as defined in any of the above, wherein said predetermined amount of DMSO is between about 1% and about 25% of the total amount of vehicle.
It is a farther object of this invention to provide such a method for producing a transdermal ointment as defined in any of the above, wherein said predetermined amount of DMSO is between about 5% and about 15% of the total amount of vehicle.
It is a farther object of this invention to provide such a method for producing a transdermal ointment as defined in any of the above, wherein said predetermined amount of DMSO is about 10% of the total amount of vehicle. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
In the following description, various aspects of the invention will be described. For the purposes of explanation, specific details are set forth in order to provide a thorough understanding of the invention. It will be apparent to one skilled in the art that there are other embodiments of the invention that differ in details without affecting the essential nature thereof. Therefore the invention is not limited by that which is described in the specification, but only as indicated in the accompanying claims, with the proper scope determined only by the broadest interpretation of said claims.
Unless specifically defined otherwise in a particular context, the terms "cannabis flowers" and "cannabis seed" as used herein refer to the flowers and seeds of any species of plant in the genus Cannabis.
As used herein, the terms "extraction," and "extracting" refer to any process known in the art by which soluble components of plant material are separated from the plant by dissolving them in a solvent, and the term "extract" refers to any solution thus obtained. The terms as used herein do not imply any restriction or limitation on the details of the process or the specific content of the extract thus produced. As used herein, the term "DMSO" refers to the chemical dimethylsulfoxide. The basic composition disclosed in the present invention comprises two components, an extract of cannabis flowers (Cannabis Flos) and an extract of cannabis seed (Cannabis Semen). The details of the extraction processes are well-known to those skilled in the art. The general methods by which the extracts are obtained in the preferred embodiments are as follows.
In one embodiment of the invention, the cannabis flower extract is obtained by ethanol extraction of cannabis flowers. In a preferred embodiment of the invention, the cannabis flower extract is obtained by extraction by 95% ethanol derived from fermentation and repeated distillation of pomegranate juice (i.e. the juice of the fruit of Punica grantwn). In a most preferred embodiment of the invention, the cannabis flower extract is obtained by extraction by 95% ethanol derived from fermentation and repeated distillation of pomegranate juice obtained from organically grown of dried flowers of Cannabis sp. In a preferred embodiment of the invention, the cannabis seed extract is obtained by cold- pressing. In another preferred embodiment, the cannabis seed extract is obtained by supercritical fluid extraction using CO2 as the solvent.
In a preferred embodiment of the invention, the cannabis flower extract is obtained from a hybrid plant of about 80% Cannabis indica and about 20% Cannabis sativa. In a most preferred embodiment of the invention, the hybrid plants from the which extracts are prepared are organically grown. In a preferred embodiment of the invention, the cannabis seed extract is obtained from seeds of Cannabis sativa. In a more preferred embodiment of the invention, the cannabis plants from which the seed extract is obtained are organically grown Cannabis sativa. In a most preferred embodiment, the organically grown Cannabis sativa from which the seed extract is prepared is a genotype with a high concentration of gamma linolenic acid (GLA) in its oil. This genotype is preferred because these seeds provide a stronger synergistic effect when their extract is combined with cannabis flower extract. The exact origin of this synergistic effect remains obscure; it appears to originate from the unexpected benefit of the combined action of THC found in cannabis flower extract with at least one of the literally dozens of natural products (e.g. other cannabinoids, terpenoids, fatty acids, sterols, etc.) found in cannabis seed extract.
In a preferred embodiment of the invention, the ratio of cannabis flower extract to cannabis seed extract within the composition is composition between about 1:99 and about 99:1. In a more preferred embodiment of the invention, the ratio of cannabis flower extract to cannabis seed extract within the composition is composition between about 5:95 and about 20:80. In a most preferred embodiment of the invention, the cannabis seed extract is provided as a base comprising about 10% pomegranate seed oil, about 5% wheat kernel oil, and about 85% cannabis seed extract, -and the ratio of cannabis flower extract to the base containing cannabis seed extract is about 5:95.
In another embodiment of the invention, the composition is compounded with an appropriate vehicle in order to produce a transdermal ointment for direct application to the skin. In a preferred embodiment of the invention, the vehicle is Cera Alba (white beeswax). In one embodiment of the invention, the ointment comprises between about 5% and about 15% of the composition described above. In a preferred embodiment of the invention, the ointment comprises between about 8% and about 12% of the composition described above. In a most preferred embodiment of the invention, the ointment comprises about 9% of the composition described above.
In another embodiment of the invention, the ointment further comprises DMSO. The DMSO is added in order to facilitate transdermal penetration of the composition into subdermal tissues. In one embodiment of the invention, the ointment comprises between about 1% and about 25% DMSO. In a preferred embodiment of the invention, the ointment comprises between about 5% and about 15% DMSO. In a most preferred embodiment of the invention, the ointment comprises about 10% DMSO. In further embodiments of the invention, the composition is provided in a form adapted for other parenteral uses including, as non-limiting examples, intravenous, nasopharyngeal, and inhalation.
The composition and ointment described above are designed to treat, lessen the effects of, and/or palliate the symptoms of a number of conditions characterized by inflammation of tissues. As described in detail in the examples presented below, these conditions include, but are by no means limited to, psoriasis, psoriatic arthritis, atopic dermatitis, and rheumatoid arthritis.
The present invention also provides a method for preparing a composition for the treatment of a condition characterized by inflammation of tissues. The method comprises the steps of (a) obtaining cannabis flower extract; (b) obtaining cannabis seed extract; and (c) mixing said cannabis flower extract and said cannabis seed extract in a predetermined ratio until a homogeneous composition is obtained. This general method will produce any of the embodiments of the composition described above, according to the ratio of the two extracts, the specific cannabis plants, and specific extraction method used.
The present invention also provides a method for preparing a transdermal ointment for the treatment of a condition characterized by inflammation of tissues. The method comprises the steps of (a) obtaining a composition for treatment of a condition characterized by inflammation of tissues as defined above and (b) compounding a said composition with a vehicle in a predetermined ratio until a homogeneous ointment is obtained. An additional embodiment of the method includes the step of adding a predetermined quantity of DMSO to the vehicle in order to prepare a transdermal ointment with increased ability to penetrate to subdermal tissues. With appropriate choices of ratio of cannabis flower extract to cannabis seed extract, specific cannabis plants, vehicle, and amount of DMSO, any of the embodiments of the transdermal ointment described above can be prepared. Example 1
Presented in this example is a typical method (given for illustrative purposes only) of cannabis flower extract as used in the invention herein disclosed. Flowers of the Erez hybrid of Cannabis indica / Cannabis sativa were carefully picked at maturity and manually trimmed with steel scissors to remove leaves. The flowers were then immediately placed in an opaque plain brown paper bag and wrapped up by the bag's own paper body. The wrapped bag was then left in a room at ambient temperature for at least two weeks and most preferably for three weeks at which time the flowers have surrendered over 80% of their fresh weight as humidity and are quite dry to the touch. The whole completely dry trimmed flowers are then weighed and 40 grams of material are placed in a dry, clean 500 ml glass bottle. This requires some little nudging but does not require outright pressing or crushing. Then 95% ethanol which is prepared from 9 successive distillations of a fermented organically grown pomegranate juice, peel, leaf and flower preparation that is obtained from Punisyn Pharmaceuticals, Ltd., Haifa, Israel is added to the jars such that the alcohol level is nearly to the top and covers all the dried flowers. In practice, this comes to 450 ml of the pomegranate alcohol which is added to the bottle containing 40 grams of dried Cannabis Flos. The metal screwcap is then adhered to the bottle tightly and it is left alone in a dark place for at least one week, and more preferably for two weeks, and most preferably for six months. Example 2
Presented in this example (for illustrative purposes only) is a typical preparation of the ointment herein disclosed. Two grams of Cera Alba are placed in a stainless steel basin which is connected to a double boiler apparatus so that the vessel is heated solely or mainly by the steam rising from an electric heating element under the double boiler. To the Cera Alba are added 1 ml wheat kernel extract (purchased from Tamar Marketing in Rishon L'Tzion Israel), 2.5 ml pomegranate seed extract (obtained by cold-press from seeds of Punica granatum, obtained from Punisyn Pharmaceuticals, Ltd., Haifa, Israel and kept at 4 degrees C in the lab), 18 ml cannabis seed extract (obtained by cold-press from seeds of Cannabis sativa and purchased from Tamar Marketing in Rishon L'Tzion Israel; the oil had been properly handled, kept in a cool dark place in opaque bottles, and stored at 4 degrees C), and 50 ml cannabis flower extract, obtained as described in the previous example. Optionally, 2.5 ml of DMSO may be further added as a penetration enhancer. The double boiler is then engaged and the mixture allowed to be heated thus at 100 degrees C until all the ethanol is evaporated and the Cera Alba discs are completely liquified. The mixture is then gently stirred with the end of a sterile syringe and the mixture is taken up into sterile plastic syringes and alllowed to cool. Once cool, the filled syringes should be stored at 4 degrees C. Example 3
A 55 year old man had suffered from acute recurrent psoriatic arthritis in his right hand for several months. His right hand was tense, edemetous and erythematous and he complained of severe pain. The ointment prepared as disclosed above was applied to the afflicted area and the patient instructed to lie down and relax. The patient slept for about 40 minutes. Upon awakening, the patient reported that the pain had remitted by 95%; the swelling and erythema had reduced by about 70%. Example 4
An 80 year old man of strong build was confined to bed for several months due to deteriorating mental status and functional inability to ambulate. Two communicating pressure ulcers, which emitted a pungent and rank odor, extended over a breadth of about 2.5 cm and a depth of about 0.5 cm on the superior buttock roughly over the hip. The patient's caretaker reported that the ulcers had been developing and expanding for two weeks prior to the start of treatment with the ointment disclosed herein. The area was thoroughly cleaned with a 3% solution of hydrogen peroxide. The ointment was then applied twice daily to the affected area and covered with a sterile dressing and adhesive tape. The caretaker reported that the ulcerss were completely closed and healed within three days of the beginning of treatment. Example 5
A 38 year old man suffered for 5 months from progressive pain in the left him, aggravated on motion. Radiography revealed a deterioration in the joint socket of the hip. Nonsteroidal anti-inflammatory drugs (NSAIDs) provided orally and topically in an ointment had afforded moderate relief for a couple of hours after each use, with gradual return of the pain. The patient then began a course of treatment with the ointment disclosed herein in place of the NSAIDs. The patient applied a small amount (-0.3 ml) of the ointment topically to the hip and massaged it in. The treatment was repeated on several occasions over the course of a week. The patient reported that the ointment provided better relief that lasted for a longer period of time than the previous course of treatment with NSAIDs had.

Claims

CLAIMS:
1. A composition for treating a condition, said composition adapted for application to the skin and said condition characterized by inflammation of tissue, wherein said composition comprises a mixture of cannabis flower extract and cannabis seed extract.
2. A composition according to claim 1, wherein the ratio of cannabis flower extract to cannabis seed extract is between about 1:99 and about 99:1.
3. A composition according to claim 1, wherein the ratio of cannabis flower extract to cannabis seed extract is between about 20:80 and about 5:95.
4. A composition according to claim 1, wherein the ratio of cannabis flower extract to cannabis seed extract is about 5:95.
5. A composition according to claim 1, wherein said cannabis flower extract is obtained by extraction with ethanol.
6. A composition according to claim 1, wherein said cannabis flower extract is obtained by extraction of dried flowers of Cannabis sp. by ethanol.
7. A composition according to claim 1, wherein said cannabis flower extract is obtained from a hybrid plant of Cannabis indica and Cannabis sativa.
8. A composition according to claim 7, wherein said hybrid plant is about 80% Cannabis indica and about 20% Cannabis sativa.
9. A composition according to claim 6, wherein said ethanol is obtained from fermentation and distillation of fruits oϊPunica grantum.
10. A composition according to claim 9, wherein said Punica grantum is organically grown.
11. A composition according to claim 1, wherein said cannabis seed extract is obtained by supercritical fluid extraction by CO2.
12. A composition according to claim 1, wherein said cannabis seed extract is obtained by cold pressing.
13. A composition according to claim 1, wherein said cannabis seed extract is obtained from seeds of Cannabis sativa.
14. A composition according to claim 13, wherein said Cannabis sativa is a genotype the seeds of which have a high gamma linolenic acid content.
15. A composition according to claim 13, wherein said Cannabis sativa is organically grown.
16. A composition according to claim 1, wherein said cannabis seed extract is provided in a base comprising about 85% cannabis seed extract, about 10% pomegranate seed oil, and about 5% wheat kernel oil.
17. A composition according to claim 16, wherein said composition comprises said cannabis flower extract and said base in a ratio of about 5:95.
18. A composition according to claim 1, wherein said condition is atopic dermatitis.
19. A composition according to claim 1, wherein said condition is psoriasis.
20. A composition according to claim 1, wherein said condition is psoriatic arthritis.
21. A composition according to claim 1, wherein said condition is rheumatoid arthritis.
22. A transdermal ointment for treating a condition characterized by inflammation of tissue, wherein said transdermal ointment comprises a composition according to claim 1 compounded with a vehicle.
23. A transdermal ointment according to claim 22, wherein said ointment comprises between about 5% and about 15% of said composition.
24. A transdermal ointment according to claim 22, wherein said ointment comprises between about 8% and about 12% of said composition.
25. A transdermal ointment according to claim 22, wherein said ointment comprises about 9% of said composition.
26. A transdermal ointment according to claim 22, wherein said vehicle is Cera Alba.
27. A transdermal ointment according to claim 22, further comprising DMSO.
28. A transdermal ointment according to claim 27, wherein said ointment comprises between about 1% and about 25% DMSO.
29. A transdermal ointment according to claim 27, wherein said ointment comprises between about 5% and about 15% DMSO.
30. A transdermal ointment according to claim 27, wherein said ointment comprises about 10% DMSO.
31. A transdermal ointment according to claim 22, wherein said condition is atopic dermatitis.
32. A transdermal ointment according to claim 22, wherein said condition is psoriasis.
33. A transdermal ointment according to claim 22, wherein said condition is psoriatic arthritis.
34. A transdermal ointment according to claim 22, wherein said condition is rheumatoid arthritis.
35. A method for producing a composition adapted for treatment of a condition characterized by inflammation of tissues, said method comprising the steps of: a. obtaining cannabis flower extract; b. obtaining cannabis seed extract; and, c. mixing said cannabis flower extract and said cannabis seed extract in a predetermined ratio until a homogeneous composition is obtained.
36. A method according to claim 35, wherein said predetermined ratio is between about 1:99 and about 99:1.
37. A method according to claim 35, wherein said predetermined ratio is between about 20:80 and about 5:95.
38. A method according to claim 35, wherein said predetermined ratio is about 5:95.
39. A method according to claim 35, wherein said step of obtaining cannabis flower extract further includes the additional step of extracting cannabis flowers with ethanol.
40. A method according to claim 39, wherein said step of obtaining cannabis flower extract further includes the additional step of obtaining dried flowers of Cannabis sp.
41. A method according to claim 35, wherein said step of obtaining cannabis flower extract further includes the additional step of extracting cannabis flowers obtained from a hybrid plant of Cannabis indica and Cannabis sativa.
42. A method according to claim 42, wherein said hybrid plant is about 80% Cannabis indica and about 20% Cannabis sativa.
43. A method according to claim 39, further comprising the additional steps of a. fermenting and distilling alcohol from fruits of Punica grantwn; and b. using said alcohol in said step of extracting cannabis flowers.
44. A method according to claim 43, wherein said Punica grantum is organically grown.
45. A method according to claim 35, wherein said step of obtaining cannabis seed extract further comprises the step of extracting cannabis seeds using supercritical CO2.
46. A method according to claim 35, wherein said step of obtaining cannabis seed extract further comprises the step of extracting cannabis seeds by cold pressing.
47. A method according to claim 35, wherein said step of obtaining cannabis seed extract further comprises the additional steps of a. obtaining seeds of Cannabis sativa; and b. producing an extract from said seeds.
48. A method according to claim 47, wherein said step of obtaining seeds of Cannabis sativa further comprises the additional step of obtaining seeds from a genotype of Cannabis sativa the seeds of which have a high gamma linolenic acid content.
49. A method according to claim 47, wherein said Cannabis sativa is organically grown.
50. A method according to claim 35, wherein said step of obtaining cannabis seed extract further comprises the additional step of preparing a base comprising about 85% cannabis seed extract, about 10% pomegranate seed oil, and about 5% wheat kernel oil.
51. A method according to claim 35, wherein said step of mixing said cannabis flower extract and said cannabis seed extract further includes the additional step of mixing said cannabis flower extract and said base in a ratio of about 5:95.
52. A method according to claim 35, wherein said condition is atopic dermatitis.
53. A method according to claim 35, wherein said condition is psoriasis.
54. A method according to claim 35, wherein said condition is psoriatic arthritis.
55. A method according to claim 35, wherein said condition is rheumatoid arthritis.
56. A method for producing a transdermal ointment adapted for the treatment of a condition characterized by inflammation of tissues, said method comprising the steps of: a. preparing a composition adapted for the treatment of a condition characterized by inflammation of tissues according to the method of claim 35; and, b. compounding said mixture with a vehicle in a predetermined ratio.
57. The method of claim 56, wherein said vehicle is Cera Alba.
58. The method of claim 56, wherein said predetermined ratio is between about 5:95 and about 15:85.
59. The method of claim 56, wherein said predetermined ratio is between about 8:92 and about 12:88.
60. The method of claim 56, wherein said predetermined ratio is about 9:91.
61. The method of claim 56, further comprising the additional step of adding a predetermined amount of DMSO to said vehicle.
62. The method of claim 61, wherein said predetermined amount of DMSO is between about 1% and about 25% of the total amount of vehicle.
63. The method of claim 61, wherein said predetermined amount of DMSO is between about 5% and about 15% of the total amount of vehicle.
64. The method of claim 61, wherein said predetermined amount of DMSO is about 10% of the total amount of vehicle.
PCT/IL2010/000486 2009-06-24 2010-06-21 Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts WO2010150245A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21979009P 2009-06-24 2009-06-24
US61/219,790 2009-06-24

Publications (1)

Publication Number Publication Date
WO2010150245A1 true WO2010150245A1 (en) 2010-12-29

Family

ID=43386085

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2010/000486 WO2010150245A1 (en) 2009-06-24 2010-06-21 Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts

Country Status (1)

Country Link
WO (1) WO2010150245A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
US9186386B2 (en) 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
WO2018006165A1 (en) * 2016-07-03 2018-01-11 3277991 Nova Scotia Limited D/B/A Truro Herbal Co. Cannabis compositions and methods
US10058531B1 (en) 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film
US10143706B2 (en) 2016-06-29 2018-12-04 Cannscience Innovations, Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
IT201800020590A1 (en) 2018-12-20 2020-06-20 Arterra Bioscience S P A Cosmetic, pharmaceutical and nutraceutical use of an extract derived from Cannabis sativa cell cultures
WO2020129046A1 (en) * 2018-12-19 2020-06-25 Pathway RX Inc. Novel cannabis lines and extracts with anti-inflammatory potencies
WO2020129044A1 (en) * 2018-12-19 2020-06-25 Pathway RX Inc. Novel cannabis lines and extracts for skin rejuvenation and skin protection
WO2020129045A1 (en) * 2018-12-19 2020-06-25 Pathway RX Inc. Novel cannabis lines and extracts for treating skin disorders
WO2020129043A1 (en) * 2018-12-19 2020-06-25 Pathway RX Inc. Novel cannabis sativa lines and extracts with anti-cancer properties

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6328992B1 (en) * 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
US20030017216A1 (en) * 2001-07-23 2003-01-23 Schmidt Robert Gustav Isolation of herbal and cannabinoid medicinal extracts
US20040049059A1 (en) * 2000-10-17 2004-03-11 Adam Mueller Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts
US20060068034A1 (en) * 2002-08-14 2006-03-30 Brian Whittle Pharmaceutical formulation
US20070032544A1 (en) * 2004-02-02 2007-02-08 Nederlandse Organisatie Voor Toegepastnatuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
US20070122492A1 (en) * 2004-11-18 2007-05-31 Stephen Behr Plant extracts and dermatological uses thereof
WO2008007123A2 (en) * 2006-07-14 2008-01-17 Astex Therapeutics Limited Pharmaceutical compounds
WO2009039843A2 (en) * 2007-09-26 2009-04-02 Letzel Heinz Plant extract from low-thc cannabis for the treatment of disease
US20090258098A1 (en) * 2008-04-15 2009-10-15 Lane Rolling Penetrating carrier, antifungal composition using the same and method for treatment of dermatophyte infections
US20100080861A1 (en) * 2008-09-05 2010-04-01 Lvmh Recherche Cosmetic or dermatological compositions comprising a mixture of essential oils, and its uses thereof, particularly for the care of sensitive or sensitized skin
US20100166891A1 (en) * 2008-12-23 2010-07-01 Intendis Gmbh Composition comprising hemp oil for treating topical diseases, especially hand-foot syndrome
US20100233128A1 (en) * 2009-03-13 2010-09-16 Mci Media Capital Inc. Natural Skin Products Containing Dairy and Processes

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6328992B1 (en) * 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
US20040049059A1 (en) * 2000-10-17 2004-03-11 Adam Mueller Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts
US20030017216A1 (en) * 2001-07-23 2003-01-23 Schmidt Robert Gustav Isolation of herbal and cannabinoid medicinal extracts
US20060068034A1 (en) * 2002-08-14 2006-03-30 Brian Whittle Pharmaceutical formulation
US20070032544A1 (en) * 2004-02-02 2007-02-08 Nederlandse Organisatie Voor Toegepastnatuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
US20070122492A1 (en) * 2004-11-18 2007-05-31 Stephen Behr Plant extracts and dermatological uses thereof
WO2008007123A2 (en) * 2006-07-14 2008-01-17 Astex Therapeutics Limited Pharmaceutical compounds
WO2009039843A2 (en) * 2007-09-26 2009-04-02 Letzel Heinz Plant extract from low-thc cannabis for the treatment of disease
US20090258098A1 (en) * 2008-04-15 2009-10-15 Lane Rolling Penetrating carrier, antifungal composition using the same and method for treatment of dermatophyte infections
US20100080861A1 (en) * 2008-09-05 2010-04-01 Lvmh Recherche Cosmetic or dermatological compositions comprising a mixture of essential oils, and its uses thereof, particularly for the care of sensitive or sensitized skin
US20100166891A1 (en) * 2008-12-23 2010-07-01 Intendis Gmbh Composition comprising hemp oil for treating topical diseases, especially hand-foot syndrome
US20100233128A1 (en) * 2009-03-13 2010-09-16 Mci Media Capital Inc. Natural Skin Products Containing Dairy and Processes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BLAKE ET AL.: "Preliminary assessment of the efficacy, tolerability and safety of a cannabis- based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.", RHEUMATOLOGY, vol. 45, no. 1, 9 November 2005 (2005-11-09), pages 50 - 52, Retrieved from the Internet <URL:http://rheumatology.oxfordjournals.org/content/45/1.toc> [retrieved on 20101019] *
KLEIN: "Cannabinoid-Based Drugs as Anti-Inflammatory Therpaeutics.", NATURE REVIEWS IMMUNOLOGY, vol. 5, no. 5, May 2005 (2005-05-01), pages 400 - 411, Retrieved from the Internet <URL:http://www.nature.com/nri/index.html> [retrieved on 20101019] *
KUPCYK ET AL.: "Cannabinoid system in the skin - a possible target for future therapies in dermatology.", EXPERIMENTAL DERMATOLOGY, vol. 18, no. 8, 24 June 2009 (2009-06-24), pages 669 - 679, Retrieved from the Internet <URL:http://www.wiley.com/bw/journal.asp?ref=0906-6705> [retrieved on 20101019] *
WARE ET AL.: "The medicinal use of cannabis in the UK: results of a nationwide survey.", INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol. 59, no. 3, March 2005 (2005-03-01), pages 291 - 295, Retrieved from the Internet <URL:http://www.blackwellpublishing.com/ijcp_enhanced> [retrieved on 20101019] *
WHITTLE ET AL.: "Prospects for New Cannabis-Based Prescription Medicines.", JOURNAL OF CANNABIS THERAPEUTICS, vol. 1, no. 3, June 2001 (2001-06-01), pages 183 - 205, Retrieved from the Internet <URL:http://www.cannabis-med.org/data/pdf/2001-03-04-11.pdf> [retrieved on 20101019] *
WILKINSON ET AL.: "Cannabinoids inhibit human keratinocyte proliferation through a non- CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 45, no. 2, February 2007 (2007-02-01), pages 87 - 92, XP005836247, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/joumal/09231811> [retrieved on 20101019], DOI: doi:10.1016/j.jdermsci.2006.10.009 *
WRIGHT ET AL.: "The use of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.", RHEUMATOLOGY, vol. 45, no. 6, June 2006 (2006-06-01), pages 781, Retrieved from the Internet <URL:http://rheumatology.oxfordjournals.org/content/45/6/781.1> [retrieved on 20101019] *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11478520B2 (en) 2014-04-17 2022-10-25 Cure Pharmaceutical Holding Corp Pharmaceutical composition and method of manufacturing
US11344591B2 (en) 2014-04-17 2022-05-31 Cure Pharmaceutical Holding Corp. Pharmaceutical composition and method of manufacturing
US11266702B2 (en) 2014-04-17 2022-03-08 Cure Pharmaceutical Holding Corp. Pharmaceutical composition and method of manufacturing
US11938160B2 (en) 2014-04-17 2024-03-26 Avenir Wellness Solutions, Inc. Pharmaceutical composition and method of manufacturing
US9186386B2 (en) 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
US10238705B2 (en) 2014-04-17 2019-03-26 Cure Pharmaceutical Holding Corp. Pharmaceutical composition and method of manufacturing
US11890310B2 (en) 2014-04-17 2024-02-06 Avenir Wellness Solutions, Inc. Pharmaceutical composition and method of manufacturing
US11331358B2 (en) 2014-04-17 2022-05-17 Cure Pharmaceutical Holding Corp. Pharmaceutical composition and method of manufacturing
US9980996B2 (en) 2014-04-17 2018-05-29 Gary J. Speier Pharmaceutical composition and method of manufacturing
US11844763B2 (en) 2014-04-17 2023-12-19 Avenir Wellness Solutions, Inc. Pharmaceutical composition and method of manufacturing
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US11304393B2 (en) 2016-05-27 2022-04-19 New West Genetics Inc. Industrial hemp cannabis cultivars and seeds with stable cannabinoid profiles
US10143706B2 (en) 2016-06-29 2018-12-04 Cannscience Innovations, Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10537592B2 (en) 2016-06-29 2020-01-21 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10383892B2 (en) 2016-06-29 2019-08-20 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
WO2018006165A1 (en) * 2016-07-03 2018-01-11 3277991 Nova Scotia Limited D/B/A Truro Herbal Co. Cannabis compositions and methods
US10765713B2 (en) 2016-07-03 2020-09-08 3277991 Nova Scotia Limited Cannabis compositions and methods
US10857125B2 (en) 2017-06-01 2020-12-08 Spartak LLC Dosage delivery film
US10307394B2 (en) 2017-06-01 2019-06-04 Spartak LLC Dosage delivery film
US10058531B1 (en) 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film
WO2020129043A1 (en) * 2018-12-19 2020-06-25 Pathway RX Inc. Novel cannabis sativa lines and extracts with anti-cancer properties
WO2020129045A1 (en) * 2018-12-19 2020-06-25 Pathway RX Inc. Novel cannabis lines and extracts for treating skin disorders
WO2020129044A1 (en) * 2018-12-19 2020-06-25 Pathway RX Inc. Novel cannabis lines and extracts for skin rejuvenation and skin protection
WO2020129046A1 (en) * 2018-12-19 2020-06-25 Pathway RX Inc. Novel cannabis lines and extracts with anti-inflammatory potencies
WO2020127056A1 (en) 2018-12-20 2020-06-25 Arterra Bioscience S.P.A. Cosmetic, pharmaceutical and nutraceutical use of an extract derived from cannabis sativa cell cultures
IT201800020590A1 (en) 2018-12-20 2020-06-20 Arterra Bioscience S P A Cosmetic, pharmaceutical and nutraceutical use of an extract derived from Cannabis sativa cell cultures

Similar Documents

Publication Publication Date Title
WO2010150245A1 (en) Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts
Jasuja et al. Pharmacological characterization and beneficial uses of Punica granatum
EP2345416B1 (en) Pharmaceutical composition for purifing vein and preparation method thereof
ITRM20080615A1 (en) FITOCOMPLESS FROM FRUIT OF BERGAMOTTO, PREPARATION PROCEDURE AND USE WHICH FOOD AND PHARMACEUTICAL SECTOR.
KR101902911B1 (en) Composition for improving human skin cell injury by UV-B comprising the extract of Hydrangea serrata
CN107411987B (en) Face acne-clearing compound essential oil and preparation method thereof
WO2013000382A1 (en) Fatty acid composition and plant extract and pharmaceutical preparation and application thereof
CN102961282A (en) Composition with penetration enhancing effect as well as preparation method and application thereof
US10967027B2 (en) Extracts of Cyclanthera pedata and formulations and uses thereof
KR100999870B1 (en) Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of Houttuynia Cordata Thub and Ulmus davidana var.Japonica as an active ingredient
EP2260855A1 (en) Composition containing aqueous extract of ashwaganda leaves as the active ingredient and method of producing the same
Gammoh et al. Evaluation of the antinociceptive effect of valerian and hops combination in experimental animal models: Involvement of the opioid system
KR101033921B1 (en) Composition for reducing irritation and inflammation in skin
KR100991399B1 (en) Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of Houttuynia Cordata, Centella asiatica, Plantago asiatica, Ulmus davidana var. Japonica and Morus alba L. as an active ingredient
KR101009904B1 (en) Antinflammatory composition comprising natural plant extract
CN110227056A (en) A kind of propolis oral cleansing lotion and preparation method thereof
CN105748545B (en) Application of Notoginseng radix converted saponin in preparing medicine for resisting fungi such as Epidermophyton floccosum, Trichophyton rubrum and Trichophyton mentagrophytes
CN108813465A (en) A kind of fig function chewable tablets and preparation method thereof
Kumar et al. Pharmacognostical, Pharmacological Studies and Traditional uses of Plectranthus Ambonicus: A Review
KR100515419B1 (en) Whitening cosmetics composition comprising natural herb extracts
KR101382137B1 (en) A composition comprising the complex extract of corylopsis gotoana and erythronium japonicum
Nge et al. The polyphenolics and health effects of pomegranate
CN106421455B (en) Sweet sorghumus extract and preparation method and application thereof
CN104524519A (en) Special handkerchief paper suitable for patient suffering cold in the bud
Belkacem et al. Antihyperglycaemic effect of hydroalcoholic extract from Punica granatum L. peels in normal and streptozotocin-induced diabetic rats and its potent α-amylase inhibitory

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10791732

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 11.05.2012)

122 Ep: pct application non-entry in european phase

Ref document number: 10791732

Country of ref document: EP

Kind code of ref document: A1